Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Charles River, WuXi PharmaTech CEOs Issue Joint Appeal For Shareholder Support

This article was originally published in The Pink Sheet Daily

Executive Summary

A shadow of suspense is expanding during the countdown to the dual shareholder meetings, since a New York-based money management firm that holds 7 percent of Charles River stock called for the abandonment of the merger plan weeks after it was unveiled in April..
Advertisement

Related Content

Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives

Topics

Advertisement
UsernamePublicRestriction

Register

PS070990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel